EP
PTGX icon

Elkfork Partners’s Protagonist Therapeutics PTGX Stock Holding History

Elkfork Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-442
Closed -$3K – 1043
2018
Q4 		$3K Buy
+442
New +$3.51K ﹤0.01% 1012

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Elkfork Partners's PTGX Position: Q1 2019 in Review

Elkfork Partners sold out of Protagonist Therapeutics (PTGX) in Q1 2019, closing a stake of 442 shares — an estimated $3K sold.

Elkfork Partners first reported a position in PTGX in Q4 2018 and held it in 1 quarter. The position peaked at $3K in Q4 2018. 64 funds tracked by Wall St. Rank hold PTGX as of Q1 2019.

  • Elkfork Partners reported no remaining Protagonist Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Elkfork Partners sold 442 Protagonist Therapeutics shares in Q1 2019, an estimated $3K.
  • Elkfork Partners first reported a position in Protagonist Therapeutics in Q4 2018 and held it in 1 quarter.
  • Elkfork Partners's Protagonist Therapeutics position peaked at $3K in Q4 2018.
  • 64 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2019.

Based on Elkfork Partners's 13F filing for Q1 2019, filed 13 May 2019.